Clinical Trials Logo

Progressive Supranuclear Palsy clinical trials

View clinical trials related to Progressive Supranuclear Palsy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04883229 Withdrawn - Clinical trials for Progressive Supranuclear Palsy

tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The investigators will test the feasibility of using transcranial direct current stimulation (tDCS) and speech therapy to treat participants with motor speech disorders caused by Frontotemporal Lobar Degeneration Pathology including nonfluent variant Primary Progressive Aphasia, Progressive Supranuclear Palsy, Corticobasal Syndrome, or behavioral variant Frontotemporal Dementia. The investigators will deliver transcranial direct current stimulation (tDCS) either in a clinic setting at the University of California San Francisco, or in patients' homes, via a consumer tDCS device and videoconferencing. Transcranial direct current stimulation (tDCS) is a neuromodulation technique that can enhance the benefits of speech therapy treatment. Participants will receive a dose of tDCS stimulation + speech therapy and a dose of sham tDCS + speech therapy in a randomized double blind crossover study performed either in the clinic or at home via videoconferencing. This study can be performed entirely remotely.

NCT ID: NCT03446807 Withdrawn - Parkinson Disease Clinical Trials

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Start date: December 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of Droxidopa for the treatment of fatigue in patients with Parkinsonism by the Visual Analog Fatigue Scale (VAFS). This is a randomized, placebo-controlled, double-blind clinical trial for 3 months where half the subjects will receive placebo and the other half will receive Droxidopa. Following this will be a wash-out period of 7 days and then all subjects will receive Droxidopa for 3 months during the open-label phase.